Obviousness

Based on the provided prior art analysis, here is an analysis of the obviousness of U.S. Patent 12,419,895 under 35 U.S.C. § 103 as of April 30, 2026.

Obviousness Analysis (35 U.S.C. § 103)

An invention is unpatentable if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA). This analysis considers combinations of the previously identified prior art references to determine if they would render the independent claims of the '895 patent obvious.

Definition of a Person Having Ordinary Skill in the Art (POSA)

A POSA in the context of this patent would be a clinical researcher or physician, such as an endocrinologist or geneticist, with experience in treating complex genetic and metabolic disorders. This individual would be knowledgeable about the pathophysiology of Prader-Willi Syndrome (PWS), including its hallmark symptoms of hyperphagia, obesity, and abnormal body composition (low lean body mass, high fat mass). The POSA would also be familiar with the standard-of-care treatments for PWS available prior to November 14, 2014, particularly growth hormone (GH) therapy, and would have a general understanding of pharmacological agents used to treat obesity and metabolic dysregulation, such as K-ATP channel openers.

---

Grounds for Obviousness of Claims 1, 8, and 12 (Monotherapy)

Combination of References: Carrel et al. (2002) in view of U.S. Patent No. 6,197,765 ('765 patent).

Reasoning:

1. Scope of the Prior Art:

   • Carrel et al. establishes that a central and well-known clinical problem in subjects with PWS is poor body composition, specifically decreased lean body mass and increased fat mass. It also establishes growth hormone (GH) as a standard therapy that favorably alters this body composition.
   • The '765 patent explicitly teaches a method of treating "central obesity" by administering diazoxide, a known K-ATP channel opener. Obesity is a primary and severe comorbidity in PWS subjects.

2. Motivation to Combine:
   A POSA is confronted with the problem of managing the severe and difficult-to-treat obesity in PWS patients, a fact underscored by Carrel et al. The '765 patent discloses that a K-ATP channel opener is an effective treatment for obesity. The motivation to combine these teachings arises from the desire to apply a known treatment for a symptom (obesity, taught in '765) to a patient population known to suffer from that specific symptom in a severe form (PWS patients, as understood from Carrel et al. and general clinical knowledge). A POSA would be motivated to seek solutions for the challenging obesity in PWS and would reasonably look to existing anti-obesity agents like diazoxide.

3. Reasonable Expectation of Success:
   By applying the teachings of the '765 patent to the PWS patient population, a POSA would have a reasonable expectation of success in achieving the outcomes claimed in the '895 patent:

   • Claim 12 (reducing body fat): This is the most direct outcome. Since the '765 patent teaches using a K-ATP channel opener to treat central obesity, a POSA would reasonably expect that administering it to an obese PWS patient would lead to a reduction in body fat.
   • Claim 1 (increasing lean body mass): A POSA understands that effective obesity treatments often improve overall body composition, not just reduce fat. By reducing the fat mass, the ratio of lean body mass to fat mass would be expected to improve, which aligns with the goal of increasing lean body mass.
   • Claim 8 (reducing hyperphagia): Hyperphagia is the primary driver of obesity in PWS. A POSA seeking to treat obesity in this specific population would understand that any effective therapy must address the underlying cause, which is excessive hunger. Therefore, applying an anti-obesity drug would lead to a reasonable expectation that it would have some effect on the hyperphagic drive.

The routine clinical parameter of administering the drug for "at least 4 weeks" to observe a meaningful change in body composition would have been an obvious design choice for a POSA.

Conclusion: Independent claims 1, 8, and 12 would likely be considered obvious over the combination of Carrel et al. and the '765 patent.

---

Grounds for Obviousness of Claims 16 and 17 (Combination Therapy)

Combination of References: Carrel et al. (2002) in view of U.S. Patent No. 6,197,765 ('765 patent).

Reasoning:

1. Scope of the Prior Art:

   • Carrel et al. teaches that GH therapy is a beneficial, standard-of-care treatment for PWS that improves lean body mass and decreases fat mass.
   • The '765 patent teaches that a K-ATP channel opener (diazoxide) can be used to treat obesity.

2. Motivation to Combine (Claim 16):
   A POSA would know from Carrel et al. that GH is the standard of care for PWS. However, they would also know that even with GH treatment, obesity and hyperphagia often remain significant, unresolved problems. There is a strong and well-established motivation in clinical practice to use combination therapies to treat complex conditions or to augment the effects of a standard-of-care treatment. A POSA would thus be motivated to add a second therapeutic agent to the existing GH regimen to achieve better control over the refractory obesity. The '765 patent identifies a K-ATP channel opener as a suitable agent for this purpose. The motivation is to achieve an additive or synergistic effect by combining two drugs with different mechanisms of action (GH acting on growth pathways, diazoxide on K-ATP channels) to treat the same overall condition.

3. Motivation to Combine (Claim 17):
   The rationale for Claim 17 is similarly strong. If a PWS patient were being treated with a K-ATP channel opener (perhaps for neonatal hyperinsulinism, a known though transient issue in PWS), it would be obvious to add the well-established, standard-of-care GH therapy taught by Carrel et al. to address the other critical aspects of the syndrome, such as poor growth and low lean body mass. Adding a proven, standard therapy to an existing treatment to provide a more comprehensive benefit is a routine and obvious clinical step.

4. Reasonable Expectation of Success:
   A POSA would have a reasonable expectation that combining these two therapies would be successful.

   • For Claim 16, adding an anti-obesity drug ('765 patent) to GH therapy (Carrel et al.) would be expected to produce a greater increase in lean body mass and decrease in fat mass than GH alone, as both agents positively affect body composition.
   • For Claim 17, the benefits of adding GH to any PWS treatment regimen are so well-documented by references like Carrel et al. that the expectation of success in increasing lean body mass would be very high.

Conclusion: Independent claims 16 and 17 would likely be considered obvious over the combination of Carrel et al. and the '765 patent, based on the well-established principle of using combination therapies to enhance a standard of care or provide more comprehensive treatment for a complex disorder.